Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Modern Pharmaceutics for Cardiovascular Diseases, 2nd Edition
share announcement

Modern Pharmaceutics for Cardiovascular Diseases, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 4921

Special Issue Editors

Prof. Dr. Radu Iliescu

E-Mail Website
Guest Editor
Department of Pharmacology, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania
Interests: physiology; pharmacology; baroreflex; blood pressure; hypertension; heart rate; cardiovascular
Special Issues, Collections and Topics in MDPI journals
Dr. Ionut Tudorancea

E-Mail Website
Guest Editor
1. 1st Medical Department, “Grigore T. Popa” University of Medicine and Pharmacy, Iași, Romania
2. Cardiology Department, Emergency Clinical County Hospital, Iasi, Romania
Interests: cardiac arrhythmias; pacemakers; heart rate variability; electrocardiography; cardiovascular pharmacology; experimental medicine; blood pressure; heart failure; hypertension; acute coronary syndromes
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Observational studies have shown that cardiovascular diseases are the leading cause of mortality in the world, and it is estimated that disturbances such as ischemic heart disease and stroke account for approximately 80% of cardiovascular disease mortality. Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases, such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, though often they are not sufficient. Moreover, despite the availability of a plethora of pharmaceutic approaches specifically targeting mechanisms involved in cardiovascular diseases over recent years, the burden of these pathologies has only been marginally alleviated. Therefore, new pharmaceutical and non-pharmaceutical strategies are necessary for both primary and secondary prevention to reduce the burden of cardiovascular diseases.

It is well known that recent advances in pharmaceutics made the development of new drugs for cardiovascular diseases, which are able to significantly improve the short- and long-term prognosis and to prevent premature deaths, possible. Thus, we are pleased to invite you to submit your original articles and/or review papers to this Special Issue which aims to highlight the advances in the development of modern pharmaceutics for cardiovascular diseases in recent years.

In this Special Issue “Modern Pharmaceutics for Cardiovascular Diseases”, original research articles and reviews from both experimental and clinical studies are welcome. Research areas may include (but are not limited to) the following: modern pharmaceutics for heart failure, arterial hypertension, pulmonary embolism, pulmonary arterial hypertension, heart rhythm disturbances, ischemic heart disease, peripheral artery disease, deep venous thrombosis, cardiomyopathies, and atherosclerosis.

We look forward to receiving your contributions.

Dr. Radu Iliescu
Dr. Ionut Tudorancea
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • pulmonary embolism
  • arterial hypertension
  • ischemic heart disease
  • deep venous thrombosis
  • cardiomyopathies
  • atherosclerosis

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 1353 KiB  
Article
Metformin Impedes Oxidation of LDL In Vitro
by Christine Rossmann, Cornelia Ranz, Gerd Kager, Gerhard Ledinski, Martin Koestenberger, Willibald Wonisch, Thomas Wagner, Sebastian P. Schwaminger, Bruno Di Geronimo, Andelko Hrzenjak, Seth Hallstöm, Gilbert Reibnegger, Gerhard Cvirn and Margret Paar
Pharmaceutics 2023, 15(8), 2111; https://doi.org/10.3390/pharmaceutics15082111 - 9 Aug 2023
Viewed by 1082
Abstract
Metformin is the most commonly prescribed glucose-lowering drug for the treatment of type 2 diabetes. The aim of this study was to investigate whether metformin is capable of impeding the oxidation of LDL, a crucial step in the development of endothelial dysfunction and [...] Read more.
Metformin is the most commonly prescribed glucose-lowering drug for the treatment of type 2 diabetes. The aim of this study was to investigate whether metformin is capable of impeding the oxidation of LDL, a crucial step in the development of endothelial dysfunction and atherosclerosis. LDL was oxidized by addition of CuCl2 in the presence of increasing concentrations of metformin. The extent of LDL oxidation was assessed by measuring lipid hydroperoxide and malondialdehyde concentrations, relative electrophoretic mobilities, and oxidation-specific immune epitopes. Cytotoxicity of oxLDL in the vascular endothelial cell line EA.hy926 was assessed using the alamarBlue viability test. Quantum chemical calculations were performed to determine free energies of reactions between metformin and radicals typical for lipid oxidation. Metformin concentration-dependently impeded the formation of lipid hydroperoxides, malondialdehyde, and oxidation-specific immune epitopes when oxidation of LDL was initiated by addition of Cu2+. The cytotoxicity of oxLDL was reduced when it was obtained under increasing concentrations of metformin. The quantum chemical calculations revealed that only the reaction of metformin with hydroxyl radicals is exergonic, whereas the reactions with hydroperoxyl radicals or superoxide radical anions are endergonic. Metformin, beside its glucose-lowering effect, might be a suitable agent to impede the development of atherosclerosis and associated CVD. This is due to its capability to impede LDL oxidation, most likely by scavenging hydroxyl radicals. Full article
(This article belongs to the Special Issue Modern Pharmaceutics for Cardiovascular Diseases, 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 1173 KiB  
Review
Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs
by Qi Jin, Dandan Chen, Xiaochun Zhang, Feng Zhang, Dongxiang Zhong, Dawei Lin, Lihua Guan, Wenzhi Pan, Daxin Zhou and Junbo Ge
Pharmaceutics 2023, 15(6), 1579; https://doi.org/10.3390/pharmaceutics15061579 - 24 May 2023
Cited by 3 | Viewed by 3067
Abstract
Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. Although the exact mechanism of PAH is not fully understood, [...] Read more.
Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. Although the exact mechanism of PAH is not fully understood, pulmonary vasoconstriction, vascular remodeling, immune and inflammatory responses, and thrombosis are thought to be involved in the development and progression of PAH. In the era of non-targeted agents, PAH had a very dismal prognosis with a median survival time of only 2.8 years. With the deep understanding of the pathophysiological mechanism of PAH as well as advances in drug research, PAH-specific therapeutic drugs have developed rapidly in the past 30 years, but they primarily focus on the three classical signaling pathways, namely the endothelin pathway, nitric oxide pathway, and prostacyclin pathway. These drugs dramatically improved pulmonary hemodynamics, cardiac function, exercise tolerance, quality of life, and prognosis in PAH patients, but could only reduce pulmonary arterial pressure and right ventricular afterload to a limited extent. Current targeted agents delay the progression of PAH but cannot fundamentally reverse pulmonary vascular remodeling. Through unremitting efforts, new therapeutic drugs such as sotatercept have emerged, injecting new vitality into this field. This review comprehensively summarizes the general treatments for PAH, including inotropes and vasopressors, diuretics, anticoagulants, general vasodilators, and anemia management. Additionally, this review elaborates the pharmacological properties and recent research progress of twelve specific drugs targeting three classical signaling pathways, as well as dual-, sequential triple-, and initial triple-therapy strategies based on the aforementioned targeted agents. More crucially, the search for novel therapeutic targets for PAH has never stopped, with great progress in recent years, and this review outlines the potential PAH therapeutic agents currently in the exploratory stage to provide new directions for the treatment of PAH and improve the long-term prognosis of PAH patients. Full article
(This article belongs to the Special Issue Modern Pharmaceutics for Cardiovascular Diseases, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop